Navigation Links
Novavax Announces Appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and Treasurer
Date:8/6/2009

ROCKVILLE, Md., Aug. 6 /PRNewswire-FirstCall/ -- Novavax, Inc. (Nasdaq: NVAX) announced today the appointment of Frederick W. Driscoll as Vice President, Chief Financial Officer and treasurer. Mr. Driscoll will report to Dr. Rahul Singhvi, Novavax's President and Chief Executive Officer.

Previously Mr. Driscoll served as Chief Financial Officer, and President and Chief Executive Officer of Genelabs Technologies, Inc. Prior to his position at Genelabs, Mr. Driscoll served in a variety of financial and senior management positions at Astraris, Inc., OXiGENE, Inc. and Collagenesis Corp. He also spent more than twenty years with Instrumentation Laboratory as vice president of finance for the Americas.

Dr. Singhvi stated: "We are pleased to welcome Fred Driscoll to Novavax as our new chief financial officer. Fred is joining Novavax at a time of significant growth and his contribution at such a critical juncture will be welcome by everyone on our Executive Team. We are looking forward to tapping into his many years of biotechnology industry experience as we expand our vaccine development programs, manufacturing operations and international collaborations."

Mr. Michael A. McManus, Jr., Novavax's Audit Committee Chairman, commented: "Mr. Driscoll is a seasoned and talented executive with valuable experience in financial management, corporate strategy and fundraising, and investor relations. Fred has had considerable experience as a public company CFO and has raised significant funds in the capital markets. In addition, he enjoys a strong reputation in the investment community. We welcome him to our Executive team."

Mr. Driscoll received his bachelor's degree in accounting from Bentley College.

About Novavax

Novavax, Inc. is a clinical-stage biotec
'/>"/>

SOURCE Novavax, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2

Related biology technology :

1. Novavax Announces Release Date of 2009 Second Quarter, Financial Results and Investor Conference Call
2. Novavax Announces Selection of a Respiratory Syncytial Virus Vaccine Candidate for Advanced Preclinical Studies
3. Novavax Announces Appointment of John J. Trizzino as Senior Vice President, International and Government Alliances
4. Novavax Announces Repayment of $5 Million of Convertible Debt
5. Cadila Pharmaceuticals Launches Joint Venture With Novavax in India
6. Spanish Government Selects Novavaxs VLP Technology for Comprehensive Flu Vaccine Solution in Spain
7. Novavax Appoints Stanley Erck to Board of Directors
8. Preclinical Proof-of-Concept Studies Published for Novavax Seasonal Influenza Virus-Like-Particle Vaccine
9. Novavax CEO to Present at Phacilitate Vaccine Forum Barcelona 2009
10. Novavax and the NIH Agree to Evaluate a Virus-like Particle (VLP) Vaccine Candidate Against the Novel Influenza A (H1N1) Virus
11. Novavax Reports First Quarter 2009 Financial Results
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:5/28/2015)... , May 28, 2015  PDS Biotechnology Corp. ... immunotherapy treatment targeting HPV-16, has generated strong T-cell ... Currently, pre-cervical cancer is treated by surgical removal ... and effective non-surgical alternative. Results show that it ... to recognize, target, and kill precancerous and cancerous ...
(Date:5/28/2015)... , May 28, 2015 Biscayne Pharmaceuticals, ... potential of its growth hormone-releasing hormone (GHRH) technology will ... 2015 ASCO Annual Meeting. The data show that the ... anti-cancer GHRH blockers, is present on many primary breast ... suggest that GHRH antagonists could have broad anti-cancer potential ...
(Date:5/28/2015)... and London (PRWEB) May 28, 2015 ... of Computer Aided Engineering software, announced today it ... Inc. (PSRI). CD-adapco will provide state-of-the-art engineering simulation ... will share their expertise and experiences in analyzing ... refining industry members and advance the understanding of ...
(Date:5/28/2015)... (PRWEB) May 28, 2015 Glenn Keet, ... The Changing Landscape of EMR/EHR Clinical Data Integration with ... taking place in Washington, DC on June 14th-18th. , ... of integrating EMR/EHR systems with EDC, and will examine ... brought by eSource and electronic health records/electronic medical records ...
Breaking Biology Technology:PDS Biotechnology reports positive Phase I clinical trial results in proprietary HPV-Cancer Immunotherapy 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 2Data Presented At 2015 ASCO Annual Meeting Shows Biscayne Pharmaceuticals' GHRH Antagonist Target Is Expressed Across All Breast Cancer Subtypes 3CD-adapco and PSRI Chartering New Course in Particle Flow Simulations 2Clinovo Presents at the DIA 2015 51st Annual Meeting in Washington, DC on June 14th-18th 2
... March 31, 2011 /PRNewswire-Asia-FirstCall/ -- China-Biotics, Inc. (Nasdaq: ... developer, manufacturer and distributor of probiotics products in China, ... sales order from its newly signed U.S. customer. ... first sales order, and formally entered into its agreement ...
... the genome engineering specialist, has announced its consolidated financial results ... Main financial items : ... 2010, from EUR 10.1M to EUR 15.8M. Growth was ... as a result of several major contracts (Boehringer Ingelheim, Bayer ...
... and US, including researchers at Arizona State University, have ... a means of producing renewable fuel. This award ... Assistant Professor Anne Jones in the department of chemistry ... efficiency of photosynthesis. This will lead to ways of ...
Cached Biology Technology:China-Biotics Receives First U.S. Sales Order 2China-Biotics Receives First U.S. Sales Order 3Cellectis Publishes 2010 Financial Results 2Cellectis Publishes 2010 Financial Results 3Cellectis Publishes 2010 Financial Results 4Cellectis Publishes 2010 Financial Results 5Biological nanowires expedite future fuel production 2
(Date:5/20/2015)... May 20, 2015 ... has announced the addition of the  ... Iris Recognition Market"  report to their ... research service analyses trends in the ... and commercial sectors, globally. Despite hardware ...
(Date:5/19/2015)... 2015 Research and ... of the  "Genetic Testing Market Outlook 2018" ... , ,A recent report, Genetic Testing Market ... the current and future genetic testing market. ... working principles and types are covered in ...
(Date:5/11/2015)... , May 11, 2015  Synaptics Incorporated (NASDAQ: ... interface solutions, today announced the appointment of ... Chief Financial Officer, reporting to Rick Bergman ... current Chief Financial Officer, Kathleen Bayless , ... Mr. Ali brings extensive financial management ...
Breaking Biology News(10 mins):Global Iris Recognition Market Report 2015 - 5-Year Opportunity Analysis 2Global Genetic Testing Market Outlook 2018 2Synaptics Appoints Wajid Ali as Senior Vice President and Chief Financial Officer 2
... the Midlands Consortium say they are absolutely delighted ... chosen to host a new 1billion national institute ... is comprised of the universities of Birmingham, Loughborough ... extensive and complementary energy related research activities. ...
... on September 27 and 28, when male contraception researchers from ... The second Future of Male Contraception conference sponsored by ... the World Health Organization, and the University of Washington ... Registration is free of charge. Here is a ...
... and Ali Saib are joint winners of the 2007 ... recipients present science in a unique format that is ... the award. Using different media, they have produced resources ... science to the broader community. Professor Ali Saib ...
Cached Biology News:Midlands Consortium delighted to be chosen to host £1 billion energy institute 2Midlands Consortium delighted to be chosen to host £1 billion energy institute 32 French scientists win European award for communication 22 French scientists win European award for communication 3
Sufficient reagents for 50 applications.Mitochondria Isolation Kit Reagent A, 50 ml Mitochondria Isolation Kit Reagent B, 500 l Mitochondria Isolation Kit Reagent C, 70 ml...
... cassette is designed to allow ampicillin selection ... gb2 driving the gene for ampicillin resistance ... Em7 promoter. It mediates higher transcription efficiency ... synthetic polyadenylation signal terminates the ampicillin expression. ...
... can be difficult to achieve in many ... one or more restriction and modification (R-M) ... recognized as "foreign". TypeOne™ Restriction Inhibitor provides ... in bacterial strains with type I R-M ...
... Y is most widely used in ... and differentially stain nucleic acids following ... dye solution, Pyronin Y stains RNA ... green. Chem comp: Dye ...
Biology Products: